DataRevive Revenue and Competitors
Estimated Revenue & Valuation
- DataRevive's estimated annual revenue is currently $10.5M per year.
- DataRevive's estimated revenue per employee is $201,000
Employee Data
- DataRevive has 52 Employees.
- DataRevive grew their employee count by -9% last year.
DataRevive's People
Name | Title | Email/Phone |
---|---|---|
1 | Principal Consultant | Reveal Email/Phone |
2 | Principal Consultant | Reveal Email/Phone |
DataRevive Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7M | 35 | -3% | N/A | N/A |
#2 | $7.2M | 36 | -5% | N/A | N/A |
#3 | $10.5M | 52 | -9% | N/A | N/A |
#4 | $344.1M | 1712 | 9% | N/A | N/A |
#5 | $27.5M | 137 | 6% | N/A | N/A |
#6 | $107.3M | 534 | 9% | N/A | N/A |
#7 | $12.9M | 64 | 28% | N/A | N/A |
#8 | $31.6M | 157 | 1% | N/A | N/A |
#9 | $31.4M | 156 | 7% | N/A | N/A |
#10 | $11.5M | 57 | 30% | N/A | N/A |
What Is DataRevive?
We are a regulatory consulting company helping pharmaceutical and biotech companies with their regulatory filings of INDs, NDAs, and BLAs in major global markets including US, China, Europe and Japan. The majority of our lead principal consultants are recent ex-FDA experts in clinical, clinical pharmacology and CMC strategies, and they deliver deep real-world global regulatory affairs expertise and hands-on support to help bring to market biologic products, small molecule drugs, vaccines, and advanced therapies including gene and cell therapies. DataRevive is a Validant Company, which means we are part of a platform that gives you access to leading specialists in every facet of the drug product lifecycle, pre- and post-approval. Contact us at info@datarevive.us to learn more.
keywords:N/AN/A
Total Funding
52
Number of Employees
$10.5M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $6.8M | 52 | -4% | N/A |
#2 | $3.4M | 52 | N/A | N/A |
#3 | $7.5M | 52 | 4% | N/A |
#4 | $8.1M | 52 | 30% | N/A |
#5 | $7M | 52 | -9% | N/A |